EOLS

Company Overview — What Does Evolus, Inc. Do?

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Evolus, Inc. (EOLS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David Moatazedi and employs approximately 170 people. With a market capitalization of $280M, EOLS is one of the notable companies in the Healthcare sector.

Evolus, Inc. (EOLS) Stock Rating — Avoid (April 2026)

As of April 2026, Evolus, Inc. receives a Avoid rating with a composite score of 27.9/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.EOLS ranks #4,170 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Evolus, Inc. ranks #739 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

EOLS Stock Price and 52-Week Range

Evolus, Inc. (EOLS) currently trades at $4.27. The stock gained $0.03 (0.7%) in the most recent trading session. The 52-week high for EOLS is $13.66, which means the stock is currently trading -68.7% from its annual peak. The 52-week low is $4.09, putting the stock 4.4% above its annual trough. Recent trading volume was 577K shares, suggesting relatively thin trading activity.

Is EOLS Overvalued or Undervalued? — Valuation Analysis

Evolus, Inc. (EOLS) carries a value factor score of 24/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 0.99x, compared to 1.66x for the average Healthcare stock.

At current multiples, Evolus, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Evolus, Inc. Profitability — ROE, Margins, and Quality Score

Evolus, Inc. (EOLS) earns a quality factor score of 31/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 359.0%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at -31.4% versus the sector average of -33.1%.

On a margin basis, Evolus, Inc. reports gross margins of 67.5%, compared to 71.5% for the sector. The operating margin is -19.7% (sector: -66.1%). Net profit margin stands at -26.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 3.1% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

EOLS Debt, Balance Sheet, and Financial Health

Evolus, Inc. has a debt-to-equity ratio of -507.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.90x, suggesting adequate working capital coverage. Total debt on the balance sheet is $146M. Cash and equivalents stand at $44M.

EOLS has a beta of 1.24, meaning it is more volatile than the broader market — a $10,000 investment in EOLS would be expected to move 24.1% more than the S&P 500 on any given day. The stability factor score for Evolus, Inc. is 27/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Evolus, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Evolus, Inc. reported revenue of $268M and earnings per share (EPS) of $-0.80. Net income for the quarter was $-71M. Gross margin was 67.5%. Operating income came in at $-52M.

In FY 2025, Evolus, Inc. reported revenue of $297M and earnings per share (EPS) of $-0.80. Net income for the quarter was $-52M. Gross margin was 66.3%. Revenue grew 11.6% year-over-year compared to FY 2024. Operating income came in at $-33M.

In Q3 2025, Evolus, Inc. reported revenue of $69M and earnings per share (EPS) of $-0.24. Net income for the quarter was $-16M. Gross margin was 66.5%. Revenue grew 12.9% year-over-year compared to Q3 2024. Operating income came in at $-12M.

In Q2 2025, Evolus, Inc. reported revenue of $69M and earnings per share (EPS) of $-0.27. Net income for the quarter was $-17M. Gross margin was 65.3%. Revenue grew 3.7% year-over-year compared to Q2 2024. Operating income came in at $-10M.

Over the past 8 quarters, Evolus, Inc. has demonstrated a growth trajectory, with revenue expanding from $67M to $268M. Investors analyzing EOLS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

EOLS Dividend Yield and Income Analysis

Evolus, Inc. (EOLS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

EOLS Momentum and Technical Analysis Profile

Evolus, Inc. (EOLS) has a momentum factor score of 15/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 32/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 53/100 reflects moderate short selling activity.

EOLS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Evolus, Inc. (EOLS) ranks #739 out of 838 stocks based on the Blank Capital composite score. This places EOLS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing EOLS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full EOLS vs S&P 500 (SPY) comparison to assess how Evolus, Inc. stacks up against the broader market across all factor dimensions.

EOLS Next Earnings Date

No upcoming earnings date has been announced for Evolus, Inc. (EOLS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy EOLS? — Investment Thesis Summary

The quantitative profile for Evolus, Inc. suggests caution. The quality score of 31/100 flags below-average profitability. The value score of 24/100 indicates premium valuation. Momentum is weak at 15/100, a headwind for near-term performance. High volatility (stability score 27/100) increases portfolio risk.

In summary, Evolus, Inc. (EOLS) earns a Avoid rating with a composite score of 27.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on EOLS stock.

Related Resources for EOLS Investors

Explore more research and tools: EOLS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare EOLS head-to-head with peers: EOLS vs AZN, EOLS vs SLGL, EOLS vs VMD.